{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:30:02Z","timestamp":1780407002499,"version":"3.54.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.<\/jats:p>","DOI":"10.1093\/cid\/ciac689","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T20:33:44Z","timestamp":1661546024000},"page":"e773-e775","source":"Crossref","is-referenced-by-count":9,"title":["Access to Medicines for Treating People With Cryptococcal Meningitis"],"prefix":"10.1093","volume":"76","author":[{"given":"Jessica","family":"Burry","sequence":"first","affiliation":[{"name":"MSF Access Campaign, M\u00e9decins Sans Fronti\u00e8res , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Perez","family":"Casas","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ford","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"2023020817031829300_ciac689-B1","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023020817031829300_ciac689-B2","author":"Rajasingham"},{"key":"2023020817031829300_ciac689-B3","volume-title":"Guidelines for diagnosing, preventing and managing cryptococcal disease in adults, adolescents and children living with HIV","author":"World Health Organization","year":"2022"},{"key":"2023020817031829300_ciac689-B4","author":"Lawrence","year":"2020"},{"key":"2023020817031829300_ciac689-B5","doi-asserted-by":"crossref","first-page":"e039191","DOI":"10.1136\/bmjopen-2020-039191","article-title":"The Lived Experience of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis","volume":"11","author":"Lawrence","year":"2021","journal-title":"BMJ Open"},{"key":"2023020817031829300_ciac689-B6","volume-title":"Guidelines for diagnosing and managing disseminated histoplasmosis among people living with HIV","author":"World Health Organization","year":"2020"},{"key":"2023020817031829300_ciac689-B7","volume-title":"WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia","author":"World Health Organization","year":"2022"},{"key":"2023020817031829300_ciac689-B8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023020817031829300_ciac689-B9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5639\/gabij.2013.0202.022","article-title":"Access to liposomal generic formulations: beyond AmBisome and Doxil\/Caelyx","volume":"2","author":"Gaspani","year":"2013","journal-title":"GaBI J"},{"key":"2023020817031829300_ciac689-B10","author":"M\u00e9decins Sans Fronti\u00e8res","year":"2021"},{"key":"2023020817031829300_ciac689-B11","author":"Banco de Pre\u00e7os em Sa\u00fade"},{"key":"2023020817031829300_ciac689-B12","author":"United Nations Development Programme","year":"2020"},{"key":"2023020817031829300_ciac689-B13","author":"Unitaid","year":"2022"},{"key":"2023020817031829300_ciac689-B14","author":"Business Standard","year":"2021"},{"key":"2023020817031829300_ciac689-B15","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/S0140-6736(05)74314-2","article-title":"Access to fluconazole in less-developed countries","volume":"356","author":"Perez-Casas","year":"2000","journal-title":"Lancet"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac689\/45869796\/ciac689.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e773\/49124533\/ciac689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e773\/49124533\/ciac689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:27:20Z","timestamp":1675877240000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/3\/e773\/6678599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,29]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac689","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,8,29]]}}}